Senior Vice President, Portfolio Strategy and Operations
Lin joined Tessera in 2021 as Head of Rare Disease Program Strategy and Operations.
Lin’s career spans broad and diverse areas of R&D, holding a variety of positions with increasing responsibilities touching on all phases of drug development. Before joining Tessera, Lin was Senior Vice President of Program and Portfolio Strategy at Xilio Therapeutics. Prior to Xilio, Lin was Senior Director of Rare Diseases at Moderna, where she was the Development Program Leader of highly visible mRNA programs and instrumental in the advancement of the Rare Diseases mRNA pipeline. Prior to Moderna, Lin held several roles with increasing responsibilities at Shire and Pfizer, where she was a subject matter expert and led teams in research and nonclinical development, pharmacogenomics and epidemiology.
Lin obtained her Ph.D. in biostatistics from Stony Brook University and completed her post-doctoral training in genetic and molecular epidemiology at the Spanish National Cancer Research Center in Madrid, Spain.